Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma

Basit Öğe Kaydı
dc.authoridPuyan, Fulya/0000-0001-5853-0109
dc.authorwosidOzyilmaz, Filiz/A-4865-2016
dc.authorwosidPuyan, Fulya/V-7074-2019
dc.contributor.authorEbru, Tastekin
dc.contributor.authorFulya, Oz Puyan
dc.contributor.authorHakan, Akdere
dc.contributor.authorVuslat, Yurut-Caloglu
dc.contributor.authorNecdet, Sut
dc.contributor.authorNuray, Can
dc.contributor.authorFiliz, Ozyilmaz
dc.date.accessioned2024-06-12T10:55:42Z
dc.date.available2024-06-12T10:55:42Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: Clear cell renal cell cancers frequently harbor Von Hippel-Lindau gene mutations, leading to stabilization of the hypoxia-inducible factors (HIFs) and their target genes. In this study, we investigated the relationship between vascular endothelial growth factor (VEGF), HIF-1 alpha, HIF-2 alpha, p53 positivity, microvessel density, and Ki-67 rates with prognostic histopathologic factors (Fuhrman nuclear grade, stage, and sarcomatoid differentiation) and survival in clear cell renal cell carcinomas. Material and Methods: Seventy-two nephrectomy specimens diagnosed as clear cell renal cell carcinoma between 2000 and 2012 were reevaluated. Immunohistochemically VEGF, HIF-1 alpha, HIF-2 alpha, p53, CD34 (for microvessel density evaluation), and Ki-67 antibodies were applied to the tumor areas. The relationships of these antibodies with prognostic factors and survival rates were evaluated with statistical analyses. Results: Mean survival time was 105.6 months in patients with ccRCC. Patients with high expression of VEGF, HIF-1 alpha and HIF-2 alpha positivity, a high Ki-67 proliferation index, and a high microvessel density evaluation score had a shorter survival time (p<0.05). Conclusions: Our findings supported that with the use of these immunohistochemical markers, prognosis of renal cell carcinoma may be predicted at the first step of patient management. New treatment modalities targeted to HIF-1 alpha and HIF-2 alpha might be planned as well as VEGF-targeted therapies in the management of clear cell renal cell carcinomas.en_US
dc.identifier.doi10.1590/S1677-5538.IBJU.2015.0521
dc.identifier.endpage454en_US
dc.identifier.issn1677-5538
dc.identifier.issn1677-6119
dc.identifier.issue3en_US
dc.identifier.pmid27583351en_US
dc.identifier.scopus2-s2.0-85020212571en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage440en_US
dc.identifier.urihttps://doi.org/10.1590/S1677-5538.IBJU.2015.0521
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19515
dc.identifier.volume43en_US
dc.identifier.wosWOS:000403885400010en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBrazilian Soc Urolen_US
dc.relation.ispartofInternational Braz J Urolen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCarcinomaen_US
dc.subjectCarcinoma, Renal Cellen_US
dc.subjectSurvival Rateen_US
dc.subjectEndothelial Growth-Factoren_US
dc.subjectMicrovessel Densityen_US
dc.subjectClinical-Significanceen_US
dc.subjectTumor Angiogenesisen_US
dc.subjectBcl-2 Expressionen_US
dc.subjectAssociationen_US
dc.subjectCanceren_US
dc.subjectKi-67en_US
dc.subjectCd34en_US
dc.subjectVegfen_US
dc.titleAnalysis of various potential prognostic markers and survival data in clear cell renal cell carcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu